团队逐年壮大，团队内学术气氛良好，实验室各种仪器、设备齐全，在临床方面和基础方面取得了一定的成绩。临床上建设急性脑梗死救治的“社区—120—院内—社区”闭环服务圈，率先开展脑卒中院前急救体系建设，脑梗死急性期干细胞的转化应用，同时设计和牵头开展国际多中心临床试验INTERACT4；基础方面建设神经系统疾病病理组织库，建设神经系统疾病干细胞库及疾病细胞模型，为我们接下来的研究打下坚实的基础。

近五年主持或参加的国家自然科学基金项目/课题：

(1) 国家自然科学基金委员会, 面上项目, 82071192, EphrinB3介导神经干细胞增殖分化对阿尔茨海默病发病及相关机制研究, 2021-01-01 至 2024-12-31, 55万元, 在研, 主持

(2) 国家自然科学基金委员会, 面上项目, 81870843, SV2A配体调控阿尔茨海默病关键神经免疫细胞功能的作用及其机制研究, 2019-01-01 至 2022-12-31, 56万元, 资助期满, 主持

近五年主持或参加的其他科研项目/课题（国家自然科学基金项目除外）：

(1) 科技部, 科技部重点研发计划, 2018YFA0107903, 临床示踪移植干细胞的组织修复与功能重建, 2018-07 至 2022-12, 2632万元, 结题, 参与

(2) 科技部, 国家重点研发计划, 2016YFA0101301, 神经系统和心脏相关重大疾病组织干 细胞和病理组织库, 2016-07 至 2020-12, 792万元, 结题, 主持

(3) 上海市科委, 重大项目, 16511105000, 面向阿尔茨海默病的社区可穿戴实时监测网 络建立与应用研究, 2016-07 至 2018-06, 400万元, 结题, 主持

(1) 国家自然科学基金委员会, 面上项目, 82071192, EphrinB3介导神经干细胞增殖分化对阿尔茨海默病发病及相关机制研究, 2021-01-01 至 2024-12-31, 55万元, 在研, 主持

(2) 国家自然科学基金委员会, 面上项目, 81870843, SV2A配体调控阿尔茨海默病关键神经免疫细胞功能的作用及其机制研究, 2019-01-01 至 2022-12-31, 56万元, 资助期满, 主持

(3) 科技部, 科技部重点研发计划, 2018YFA0107903, 临床示踪移植干细胞的组织修复与功能重建, 2018-07 至 2022-12, 2632万元, 结题, 参与

(4) 科技部, 国家重点研发计划, 2016YFA0101301, 神经系统和心脏相关重大疾病组织干 细胞和病理组织库, 2016-07 至 2020-12, 792万元, 结题, 主持

(5) 上海市科委, 重大项目, 16511105000, 面向阿尔茨海默病的社区可穿戴实时监测网 络建立与应用研究, 2016-07 至 2018-06, 400万元, 结题, 主持

1. Curcumin-driven reprogramming of the gut microbiota and metabolome ameliorates motor deficits and neuroinflammation in a mouse model of Parkinson's disease. Cui Can, Yingying Han, Hongxia Li, Hongxiang Yu, Bei Zhang and Gang Li. Frontiers in cellular and infection microbiology 2022.

2. Mechanical Thrombectomy for Acute Stroke Due to Large-Vessel Occlusion Presenting With Mild Symptoms. Liu Feifeng, Hao Shen, Chen Chen, Huan Bao, Lian Zuo, Xiahong Xu, Yumei Yang, A. Cochrane, Yaping Xiao and Gang Li. Frontiers in neurology 2021.

3. Stroke Patients with Faster Core Growth have Greater Benefit from Endovascular Therapy. Longting Lin, Hao Zhang, Chushuang Chen, Andrew Bivard, Kenneth Butcher, Carlos Garcia-Esperon, Neil J. Spratt, Christopher R. Levi, Mark W. Parsons, Gang Li. Stroke 2021.

4. High-Density Lipoprotein Cholesterol and the Risk of First Ischemic Stroke in a Chinese Hypertensive Population. Yue Zhang,Jingyi Li, Chengzhang Liu, Hongxiang Yu,Chen Chen,Chonglei Bi, Chongqian Fang, Hai Ma,Aimin Li,Qing Dong, Lishun Liu,Binyan Wang, Xiao Huang, Xiaoshu Cheng, Pierre Zalloua,Xiping Xu, Yong Huo, and Gang Li. Clinical Interventions in Aging，2021,05

5. Association of HMOX-1 with sporadic Alzheimer’s disease in southern Han Chinese. Bei Zhang, Hong-Xiang Yu, Nan Zhi, Can Cui, Ying-Ying Han, Min Hu, Hao Shen, Huan Bao, Gang Li. European Journal of Neurology, 2021.

6. Increased GABAergic Development in iPSC-Derived Neurons from Patients with Sporadic Alzheimer’s Disease, Yueyu Tang, Yingying Han, Hongxiang Yu, Bei Zhang, and Gang Li. Neuroscience Letters,2020,06

7. Association between ZNF184 and symptoms of Parkinson's disease in southern Chinese. Zhang B, Cui C, Yu H, Li G. Neurol Sci. 2020 Mar 3. doi: 10.1007/s10072-020-04309-5.

8. Association between fatigue and motor progression in Parkinson's disease in southern Chinese. Yu HX, Guo MR, Li G, Zhang B. Neurol Sci. 2020 Jan;41(1):161-164. Epub 2019 Sep 4

9. Therapeutic Effect on Acute Cerebral Infarction is Enhanced after Nanoceria-Labeling on Human Umbilical Cord Mesenchymal Stem Cells. Zuo L, Feng Q, Han Y, Chen M, Guo M, Liu Z, Cheng Y, Li G. Therapeutic Advances in Neurological Disorders, 2019 Jul 30;12:1756286419859725.

10. Clinical and laboratory factors related to acute isolated vertigo or dizziness and cerebral infarction. Zuo L, Zhan Y, Liu F, Chen C, Xu L, Calic Z, Cordato D, Cappelen-Smith C, Hu Y, Li G. Brain Behav. 2018, 8:e01092.

11. Establishment of TUSMi003-A, an induced pluripotent stem cell (iPSC) line from a 62-year-old Chinese Han patient with Alzheimer's disease with ApoE3/4 genetic background. Wang Y, Yu H, Zhang Y, Zhang J, Chen K, Sun H, Meng S, Li G, Lei Y, Zhao J. Stem Cell Res. 2018, 27:57-60.